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a crucial role in mediating the vasorelaxant
activity of Gynura procumbens
Hien-Kun Ng, Ting-Fung Poh, Sau-Kuen Lam and See-Ziau Hoe*Abstract
Background: Previous studies of Gynura procumbens (G. procumbens) have shown that partially purified fractions of
the leaves are capable of lowering the blood pressure of rats by inhibiting angiotensin-converting enzymic activity
and causing vasodilatation. The objectives of this study were therefore to further purify the active compounds that
exhibited selective effects on blood vessels, determine the mechanism of actions, and to qualitatively analyse the
putative compounds present.
Methods: The butanolic fraction (BU) of the crude ethanolic extract was purified using column chromatography to
obtain several sub-fractions of different polarities. The in vitro effects of BU and the sub-fractions on vascular tension
were subsequently determined using isolated rat thoracic aortic rings. The most potent sub-fraction (F1) alone was
then investigated for its mechanisms of the vasorelaxant activity. In another experiment, thin-layer chromatography
was used to qualitatively analyse the active compounds found in F1.
Results: The BU and the sub-fractions ranging from 10-7 to 10-2 g/ml significantly (p < 0.05) inhibited the sustained
tonic contractions induced by phenylephrine and potassium chloride in a concentration-dependent manner with
various degree of potency. The most potent sub-fraction (F1) antagonised the calcium-induced vasocontractions
(1 x 10-4 – 1 x 10-2 M) in calcium-free with high concentration of potassium as well as in calcium- and
potassium-free Krebs-Henseleit solutions. Contractions induced by noradrenaline and caffeine were not affected by
F1. The vasorelaxing effect caused by F1 was significantly attenuated with preincubation of potassium channel
blockers (glibenclamide and 4-aminopyridine) and prostacyclin inhibitor (indomethacin) while it was not affected by
preincubation with tetraethylammonium, l-nitro-arginine methyl esther, propanolol, atropine, oxadiazolo quinoxalin
one and methylene blue. The qualitative phytochemical analysis of F1 indicated the presence of flavonoids.
Conclusion: These results confirm previous findings that G. procumbens causes vasodilatory effects by blocking
calcium channels. In addition, the present study further demonstrates that the vasodilatory effect of G. procumbens
may also be due to the opening of potassium channels and the stimulation of prostacyclin production.
The putative compounds are probably flavonoids in nature.
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Hypertension is defined as a condition where there is
persisting high arterial pressure with systolic and diastolic
blood pressure (BP) exceeding 140 mmHg and 90 mmHg
respectively [1]. Hypertension is a high prevalent risk fac-
tor for cardiovascular diseases (CVD) throughout the in-
dustrial world and it is becoming a common health
problem worldwide because of increasing longevity and
the prevalence of contributing factors such as obesity,
physical inactivity, and unhealthy diets. Cardiovascular
disease is responsible for one third of global deaths and is
a leading contributor to the global disease burden [2].
Therefore, the search for a safe and effective method for
controlling hypertension has been a continuous effort
world-wide. In addition to conventional synthetic drugs
like thiazide and captopril [3], naturally occurring com-
pounds from plant origin have also been highly sought by
researchers.
One of the major determinants of BP is the total periph-
eral resistance (TPR), which is determined by the con-
tractile state of blood vessel or vascular tone. In view of its
defining role in regulating BP, vascular reactivity has be-
come a target in treating hypertension. With the advent of
the direct vasodilator, hydralazine, in the early 1950s [4],
many drugs that can cause vascular relaxation have been
developed, including some plant-derived compounds.
Gynura procumbens (G. procumbens) (Lour.) Merr. or
the local names of sambung nyawa (Malay) or jian wei
feng (Chinese), from the family of Compositae, and a fast
growing herbaceous plant, is found in Borneo, Java, the
Philippines and Peninsular Malaysia. The plant is widely
used to treat kidney diseases, rashes and fever and the
leaves of the plant have been used in folk medicine as an
antihypertensive agent [5].
A lot of effort and studies have been carried out in order
to scientifically prove the pharmacological properties of
G. procumbens. Ethanolic extract of G. procumbens leaves
have been shown to possess antihyperglycaemic and
antihyperlipidaemic activities in diabetic rats [6,7], and the
n-butanol fraction from the G. procumbens leaves also has
hypoglycaemic effects [8]. Another study had shown that
hexane and ethyl acetate fractions have potential in stimu-
lating glucose uptake in 3 T3-F44 adipocytes [9]. Steroids
isolated from the plant have been proven to possess anti-
inflammatory activity [10]. Furthermore, ethanolic ex-
tract of it has demonstrated anti-ulcerogenic activity
[11] and was able to inhibit ultraviolet (UV) B-induced
matrix-metalloproteinase expression in human dermal
fibroblasts [12]. Methanolic extract of G. procumbens
has been categorised as a no-observed-adverse-effect
level (NOAEL) crude drug that acts harmlessly and is
considered to be of no toxicological concern [13]. Its
aqueous extract appears to inhibit human mesangial cell
proliferation [14].Gynura procumbens has also been found to demon-
strate antihypertensive activities in rat [15] by inhibiting
ACE activity [16] and cause vasodilation via inhibition of
calcium channels [17].
The main purpose of the present study was to further
purify the active compounds that exhibit selective effects
on the blood vessels, determine the mechanism of actions,




Fresh G. procumbens were collected from the southern
part of Peninsular Malaysia and authenticated by the
Institute of Biological Sciences, University of Malaya. A
voucher specimen (KLU 047690) had been deposited in
the Herbarium at Rimba Ilmu, University of Malaya.
Animals
Adult male SD rats, weighing from 200 – 300 g, were
obtained from the Experimental Animal Center, University
of Malaya. All the rats were kept under standard condition,
given standard rat chow and tap water ad libitum. All
experimental procedures that involve animal studies were
approved by the University of Malaya Medical Center
Animal Ethics Committee (FIS/14/10/2009/NHK (R)).
Drug and chemicals
For extraction and fractionation processes, ethanol,
ethyl acetate, hexane, methanol, and n-butanol were
purchased from R & M Marketing, Essex, U.K. For the
in vitro aortic ring pharmacological intervention, 4-
aminopyridine, acetylcholine chloride (ACh), ACE, atro-
pine sulphate, Brilliant Blue-G dye, caffeine anhydrous,
glibenclamide, indomethacin, L-nitro-arginine methyl ester
(L-NAME), noradrenaline (NA), oxadiazolo quinoxalin
one (ODQ), phenylehprine (PE), propranolol hydrochlor-
ide, tetraethylammonium (TEA) were purchased from
Sigma-Aldrich CO., St Loius, MO, USA. Ingredients for
Krebs-Henseleit (K-H) solution were purchased from Merck
KGaA, Darmstadt, Germany. All water-soluble drugs were
dissolved in the distilled water before use while the water-
insoluble drugs were dissolved in 15% tween 80 solution.
Extraction and purification
The leaves of the plant were washed, cleaned of adulterants
and dried in an oven at 40°C for 72 hours. The dried leaves
were then ground into fined powder using a grinder. Crude
ethanolic extract was obtained by macerating the powder
with 95% ethanol at room temperature for 3 days. The ex-
tract was then concentrated by using rotary evaporator and
reconstituted in 80% aqueous ethanol. The resulting frac-
tion was then partitioned with hexane for the removal of
the lipid or non-polar compounds. The hexanic phase was
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tion (HX). The aqueous ethanolic phase obtained was
subjected to evaporation to remove the ethanol and pro-
duce the aqueous solution that contained ethanol-soluble
precipitate (EH). The precipitate was then filtered out and
the remaining solution was partitioned again with water-
saturated n-butanol. The butanolic phase was then dried
using the rotary evaporator and lyophilised to obtain BU
whilst the remaining aqueous phase was lyophilised to ob-
tain the final aqueous fraction (FA). Since the fraction BUFigure 1 Summary of extraction and purification of G. procumbens le
successively partitioned with different solvents to obtained the butanolic fr
(F1 – F8). Fraction 1 was subjected to further studies due to its highest vasshowed the highest vasorelaxing activities from previous
studies [17], it was subjected to further purification.
The BU was further purified by using column chroma-
tography packed with silica gel 60 (0.063 – 0.200 nm) as
the stationary phase. It was dissolved in ethanol and ap-
plied to the packed column. Eight different solvent mix-
tures that consisted of different proportions of ethyl
acetate, methanol and water were used as the mobile
phases of the column chromatography with the polarities
increasing from mobile phases 1 to 8. Each sub-fractionaves. Dried ground leaves were extracted with 95% ethanol and
action (BU), which was then further purified into 8 sub-fractions
odilatory activities.
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most active fraction was subjected to further studies.
Figure 1 shows the flow chart of extraction, fraction-
ation and purification procedures of the crude extract
of G. procumbens leaves.Phytochemical screening
The sub-fraction that achieved the highest activity in the
vasorelaxing effect was subjected to phytochemical screen-
ing by thin layer chromatography (TLC). The stationary
phase used was TLC plate pre-coated with silica gel
60 F254 on aluminium sheets and the mobile phase used
was a mixture of ethyl acetate (75%), methanol (10%),
deionised water (10%) and formic acid (5%). Naturstoff
reagent, ninhydrin reagent, and diphenylamine-aniline-
phosphoric acid reagent were used for the detection of
flavonoids, proteins, and sugar moieties respectively.In vitro vascular tension studies
Male SD rats weighing 250 – 300 g were sacrificed by cer-
vical dislocation and the thoracic aorta was located. The
throracic aorta was isolated and immediately placed in an
oxygenated K-H solution made up of the following com-
position (in mM): NaCl, 118.0; KCl, 4.70; CaCl2, 1.25;
MgSO4, 1.2; KH2PO4, 1.2; NaHCO3, 24.9 and glucose,
11.1. Adhering fat and connective tissue were carefully re-
moved and the aorta was cut into rings of 1 – 3 mm in
length. The aortic ring was mounted by 2 stainless steel
holders in an organ bath containing 10 ml K-H solution
and continuously bubbled with 95% oxygen and 5% carbon
dioxide gas mixture. The K-H solution was maintained at
37°C by a circulating water bath system. One of the holders
was served as an anchor while the other side was
connected to a force transducer to measure the isometric
tension developed. The force transducer was connected to
a Powerlab system which displayed the responses onto the
screen of a personalised computer that was installed with
the software Powerlab Chart version 5.0.
A basal tension of 1 g was applied to each ring. Each
preparation was allowed to equilibrate for 60 minutes
with the changing of the K-H solution every 15 minutes
before the start of the experiments. Aortic rings were
stimulated with KCl (6 x 10-2 M) for 3 times to confirm
the production of reproducible contractile responses.
Aortic rings were denuded to remove the endothelial
layer in some preparations by inserting a pair of forceps
into the lumen of the aorta and gently rotating them.
The viability of each aortic ring was validated by
precontraction of PE (1 x 10-6 M) and relaxed by ACh
(1 x 10-5 M) just before the experiment. Relaxation
of ≥ 70% indicated the presence of a functional or in-
tact endothelial layer while the lack of relaxation indi-
cated the successful removal of the layer.Effects of BU and sub-fractions (F1 – F8) on aortic rings
precontracted with PE or KCl
The intact aortic rings were precontracted by the addition
of PE (1 x 10-6 M) or KCl (8 x 10-2 M). After the tonic re-
sponses or contractions became stable, increasing concen-
trations of the test fractions (10-7 – 10-2 g/ml) were added
cumulatively. F1 was subjected to further studies due to
its highest activity in producing the vasorelaxing effect.
Effects of F1 on calcium (Ca2+) channel activities
In order to investigate whether F1 could interfere with the
influx of Ca2+ through voltage-dependent calcium channel
(VDCC), aortic rings were exposed to Ca2+-free solution
in the presence of potassium ion (K+; 6 x 10-2 M). The
preparation of the solution had the same composition with
the normal K-H solution except that CaCl2 was excluded
and EDTA (1 x 10-4 M) added to eliminate the extracellular
Ca2+. Each aortic ring was exposed to this solution for 60 mi-
nutes. Two successive cumulative concentration-response
curves for Ca2+ (1 x 10-4 – 1 x 10-2 M) were obtained. The
first curve was obtained without the incubation of F1, after
which the aortic ring was washed and allowed to equilibrate
for 60 minutes in the solution. Two different concentrations
of F1 (2.0 mg/ml and 4.0 mg/ml) were added to the organ
bath and allowed to incubate for 30 minutes, after which
the second curve was obtained. Each aortic ring was
exposed to only one concentration of F1.
To investigate the inhibitory effect of F1 on receptor-
operated calcium channel (ROCC), Ca2+- and K+-free
K-H solution was used in the experiment. The compo-
sition of the solution was the same with Ca2+-free K-H
solution except that 1.2 mM of NaH2PO4 was used to
replace the 1.2 mM of KH2PO4. After the equilibration,
PE (1 x 10-6M) was added to induce a transient contrac-
tion. As the contraction became stable, cumulative con-
centrations of Ca2+ (1 x 10-4 – 1 x 10-2 M) were added
to obtain the first curve. After that, the aortic ring was
washed with normal K-H solution and incubated for
45 minutes. The solution was then replaced with Ca2+-
and K+-free K-H solution. Two different concentrations
of F1 (2.0 mg/ml and 4.0 mg/ml) were added to the
organ bath and allowed to incubate for 30 minutes. Cu-
mulative concentrations of Ca2+ were added to obtain
the second curve. Each aortic ring was exposed to only
one concentration of F1.
To elucidate whether the F1 could affect the release of
Ca2+ from intracellular store, NA and caffeine were used.
The aortic ring was exposed to Ca2+- free K-H solution for
15 minutes after the equilibration in normal K-H solution.
Noradrenaline (1 x 10-6 M) or caffeine (4.5 x 10-2 M) was
added to induce a transient contraction. The ring was then
washed and incubated with normal K-H solution for
45 minutes to replenish the intracellular Ca2+ store. After
that, the medium was replaced with Ca2+- free K-H
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adrenaline or caffeine was added after the incubation with
F1 (2.0 mg/ml and 4.0 mg/ml) for 15 minutes. Each aortic
ring was exposed to only one concentration of F1.
Effects of F1 on potassium (K+) channel activities
In order to investigate whether the F1 could affect the K+
channel opening during vasorelaxation, 4-aminopyridine
(1 mM), a blocker of the voltage-activated K+ channel; TEA
(1 mM), a selective blocker to Ca2+-activated K+ channel;
and glibenclamide (10 μM), a blocker of ATP-sensitive K+
channel were used in the experiments. All of the blockers
were added in the organ bath 15 minutes before the aortic
rings were precontracted with PE. After the tonic contrac-
tions had become stable, increasing concentrations of F1
(10-7 – 10-2 g/ml) were added cumulatively. The relaxation
curves obtained were then compared with the control
curve which were not treated with any of the blockers. Each
aortic ring was exposed to only one blocker [18].
Effects of F1 on the endothelium-denuded aortic rings
precontracted with PE, NO and prostacyclin productions,
and guanylyl cyclase activity
To study the involvement of endothelium in the vasore-
laxation effect of F1, endothelium-denuded aortic rings
were used. The denuded aortic rings were precontracted
with PE before cumulative doses of F1 were added. After
the tonic contractions became stable, increasing concen-
trations of F1 (10-7 – 10-2 g/ml) were added cumulatively.
The possible inhibitory effects of F1 on the release of
two endothelium-derived releasing factor (EDRF), NO and
prostacyclin, as well as its effect on the guanylyl cyclase, a
key enzyme in the NO-mediated vasodilation pathway,
were also investigated. In these series of experiments, the
NO synthase inhibitor, L-NAME; the non-selective inhibi-
tor of prostacyclin production, indomethacin; as well as
two of the guanylyl cyclase inhibitors; ODQ and methy-
lene blue, were used.
After the endothelium-intact aortic rings had equili-
brated, the drugs were added to the organ bath 15 minutes
before the addition of PE. As the PE-induced contraction
reached a steady stage, increasing concentration of F1
(10-7 – 10-2 g/ml) were added cumulatively. The relaxation
curves obtained were compared to the control curve [19].
Each aortic ring was exposed to only one type of drug.
Effects of F1 on autonomic receptor activities
To study whether the vasodilation activity of F1 is re-
lated to autonomic receptors, propranolol (1 μM), a beta
adrenoceptor blocker and atropine (1 μM), a muscarinic
receptor blocker, were used. Both drugs were added to
the organ bath 15 minutes before the addition of PE.
After the tonic contractions caused by PE became stable,
increasing concentrations of F1 (10-7 – 10-2 g/ml) wereadded cumulatively. Each aortic ring was exposed to
only one type of drug.
Statistical analysis
Changes in the relaxation were calculated as percentage
change of maximal contraction induced by PE or KCl. The
pIC50 value is calculated as the concentration of BU or F1
to produce 50% reduction of the maximal contraction in-
duced by PE or KCl. For the cumulative dose–response
curves of Ca2+, data from experiments in the presence or
absence of the test fraction were compared. The maximal
contraction (Emax) obtained in the 1st response curve of
Ca2+ was taken as 100% and all the following contractions
were calculated as a percentage of these values. The con-
centration of Ca2+ required to produce 50% of the ma-
ximal contraction was taken as pEC50 (−log EC50).
In the experiment that involved NA and caffeine,
changes in NA- or caffeine-induced contractions in the
presence of F1 were expressed as percentages of the initial
contraction before incubation of F1. All the analyses were
performed by computer program Graphpad Prism 5 using
non-linear regression of concentration-response curve. All
values are expressed as mean ± S.E.M for n numbers of
rings. Statistical differences are evaluated by Student t-test.
A probability level of less than 0.05 (p < 0.05) is considered
to be significantly different.
Results
Extraction and purification
Extraction of dried G. procumbens leaves with 95% ethanol
and the subsequent fractionation lead to the production of
various fractions with different percentage of yields. The
yield obtained from BU was approximately 2%. Further
purification of BU using column chromatography resulted
in 8 sub-fractions (F1 – F8) of which F1, F2 and F3 con-
tributed to most of the yields, accounting for 20%, 24%
and 35% respectively.
Phytochemical screening
High amount of flavonoids, which fluoresce under ultra-
violet light at 365 nm after spraying with Naturstoff re-
agent, were detected.
Effects of BU and sub-fractions (F1 – F8) on aortic ring
precontracted with PE or KCl
The BU fraction at the concentrations ranging from
10-7 – 10-2 g/ml significantly (p < 0.05) inhibited the
sustained tonic contraction induced by PE and KCl in a
concentration-dependent manner. The maximal relax-
ation responses caused by BU, or Rmax, in the aortic
rings precontracted with PE and KCl were 85.39 ±
4.26% and 53.30 ± 6.14%, respectively and the pIC50
values were 2.57 ± 0.06 and 2.06 ± 0.08, respectively
(Figure 2).
Figure 3 Concentration-relaxation curves for the 8 sub-fractions
in the isolated rat aortic rings. The fractions-induced relaxations
were studied on endothelium-intact aortic rings precontracted with
either (a) PE or (b) KCl. Values are mean ± S.E.M (n = 6), *P < 0.05
compared with other sub-fractions.
Figure 2 Concentration-relaxation curves for the BU fraction in
the isolated rat aortic rings. The BU-induced relaxation was
studied on endothelium-intact aortic rings precontracted with either
PE or KCl. Values are mean ± S.E.M (n = 8).
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the column chromatography at concentrations ranging
from 10-7 - 10-2 g/ml significantly inhibited the sustained
tonic contractions induced by PE. The Rmax value
achieved by F1 was 98.39 ± 5.79% with pIC50 value of
2.62 ± 0.002 and both of these values were significantly
different (p < 0.05) with that shown by all other sub-
fractions (Figure 3, Table 1)
For the aortic ring precontracted with KCl, F1 also
achieved the highest percentage of relaxation with the
Rmax = 84.40 ± 24.04% and pIC50 = 2.54 ± 0.003, respect-
ively. There was no significant difference in the percent-
age of relaxation that caused by F1 if compared with F2
and F3. (Figure 3, Table 1).
In view of the finding that the relaxant effect of F1 is the
highest and significantly different from that of the BU and
other fractions, it was subjected to further studies.
Effects of F1 on calcium channel activities
As shown in Figure 4, CaCl2 caused a concentration-
dependent contraction of aortic rings that had been ex-
posed to a Ca2+-free medium with high concentration of
K+. The Emax values were significantly reduced by
preincubation of the rings with F1 at 2.0 x 10-3 mg/ml
(p < 0.05) and 4.0 x 10-3 mg/ml (p < 0.01) in a
concentration- dependent manner (Table 2). The pEC50
values were also reduced in the presence of F1.
In a Ca2+- and K+-free medium, Ca2+ (1 x 10-4 – 1 x
10-2 M) was cumulatively added to the organ bath after PE
had induced a stable tonic contraction. Sustained contrac-
tion was generated which increased with the concentration
of Ca2+. The Ca2+- induced contraction was significantly
inhibited by the preincubation of the aortic ring with F1
(2.0 x 10-3 and 4.0 x 10-3 mg/ml) in a concentration-
dependent manner (Figure 5). F1 significantly (p < 0.01)suppressed the Emax values of CaCl2 with the reduction
of the pEC50 values (Table 2). Results in Figure 6 show
that the contractions induced by either NA or caffeine in
Ca2+-free solution were not significantly affected by F1.Effects of F1 on potassium channel activities
As shown in Figure 7, preincubation with glibenclamide
and 4-aminopyridine caused significant reductions in the
Rmax values caused by F1. Similarly, the pIC50 values
were reduced in the presence of these 2 drugs (Table 3).
However, there was no significant difference found be-
tween the F1-induced relaxation curves of the aortic
rings preincubated with TEA and the control curve. The
Table 1 The effects of BU-derived sub-fractions in aortic
rings precontracted with PE or KCl
Fraction PE KCl
Rmax (%) pIC50 Rmax (%) pIC50
1 98.39 ± 5.79* 2.62 ± 0.09* 84.40 ± 24.04 2.54 ± 0.15
2 56.57 ± 20.90 2.04 ± 0.35 69.54 ± 18.08 2.34 ± 0.18
3 67.21 ± 12.33 2.24 ± 0.08 57.45 ± 13.09 2.13 ± 0.15
4 14.02 ± 3.92 - 24.54 ± 8.67 -
5 32.47 ± 9.12 - 43.01 ± 6.93 -
6 24.35 ± 8.74 - 15.15 ± 3.72 -
7 7.84 ± 1.57 - 12.85 ± 3.52 -
8 11.38 ± 2.75 - 18.38 ± 4.99 -
Values are means ± S.E.M (n = 6). *P < 0.05 compared with other sub-fractions.
Figure 4 Effect of F1 on CaCl2-induced contraction in Ca
2+-free
solution containing high K+ (60 mM). Concentration-response
curves for CaCl2 were determined in aortic rings in the absence
and presence of F1 (2 or 4 mg/ml). Values are mean ± S.E.M. (n = 6).
*P < 0.05 and **P < 0.01 compared with control (without F1).
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by the incubation with TEA.
Effects of F1 on the endothelium-denuded aortic rings
precontracted with PE, NO and prostacyclin productions,
and guanylyl cyclase activity
The Rmax and pIC50 of endothelium-denuded aortic
rings are 93.28 ± 3.02% and 2.44 ± 0.09 respectively,
which are not significantly different from the control
values of 98.39 ± 5.79% and 2.62 ± 0.09 respectively. Be-
sides that, the vasorelaxing effect (Rmax and pIC50) in-
duced by F1 were also not significantly affected by
preincubation of L-NAME, ODQ, and methylene blue.
Nonetheless, preincubation of indomethacin caused sig-
nificant reductions in both the Rmax and pIC50 values of
F1 (Figure 8, Table 3).
Effects of F1 on the autonomic receptor activities
As shown in Figure 9, the vasorelaxing effects of F1
against PE-precontracted aortic rings were not signifi-
cantly inhibited by the preincubation with atropine or
propranolol. In both experiments, the Rmax and pEC50
values did not show any significant difference with that
of the control (Table 3).
Discussion
In the present study, BU was found to cause relaxation on
the endothelium-intact aortic rings that had been




Ca2+-free solution containing high K+
Emax (%) pEC50
0 100 3.35 ± 0.08
2.0 86.33 ± 5.44* 3.31 ± 0.19
4.0 50.04 ± 12.06** 3.24 ± 0.42
Values are means ± S.E.M (n = 6). *P < 0.05 and **P < 0.01 compared with control (0the results reported in a previous study [17] that BU may
reduce BP by vasodilation. BU was then further purified
by column chromatography using solvent mixtures of dif-
ferent polarities. It was found that F1 demonstrated the
highest vasodilatory activity and the effect was more pro-
found (p < 0.05) when compared with BU-induced vasore-
laxation. This indicates that most of the putative active
compounds of BU appear to be concentrated in F1.
Phenylephrine activates the α1-adrenoceptors in the VSM
to cause the muscle contraction involving phospholipase
C (PLC) and 1,2-diacylglycerol (DAG) [20,21] while KCl
causes the depolarisation of the VSM cell membrane,
opening of VDCC and influx of Ca2+ in order to cause
contraction [22]. Both BU- and F1 induced relaxation in
aortic rings precontracted with PE or KCl, suggesting that
they might inhibit both the activation of α1-adrenoceptors
and opening of the VDCC.
It is well known that vasoconstriction is initiated by
elevated levels of the free cytoplasmic Ca2+ which can
either be due to the influx of extracellular Ca2+ upon
opening of the VDCC and ROCC located on the cell
membrane [22,23] or the release of Ca2+ from sarco-
plasmic reticulum (SR) [24,25]. To investigate whether
F1 could interfere with the Ca2+ influx through VDCC,Ca2+ and K+-free solution containing PE
Emax (%) pEC50
100 3.73 ± 0.21
75.33 ± 10.33** 3.61 ± 0.27
44.93 ± 11.46** 3.34 ± 0.48
mg/ml of F1.
Figure 7 Concentration-relaxation curves for F1 in the isolated
rat aortic rings. The F1-induced relaxation was studied on PE-
precontracted endothelium-intact aortic ring preincubated with TEA
or glibenclamide or 4-aminopyridine. Values are mean ± S.E.M (n = 6).
*P < 0.05 compared with control (without blocker).
Figure 5 Effect of F1 on CaCl2-induced contraction in Ca
2+- and
K+-free solution containing PE. Concentration-response curves for
CaCl2 were determined in aortic rings in the absence and presence
of F1 (2 or 4 mg/ml). Values are mean ± S.E.M. (n = 6). **P < 0.01
compared with control (without F1).
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2+-free with high K+
medium was used. Under high concentrations of K+, the
added Ca2+ will cause the influx of Ca2+ through the
VDCC [22]. Whereas to investigate whether F1 could
interfere with the Ca2+ through ROCC, Ca2+- and
K+-free medium containing PE was used. Addition of
PE in the Ca2+-and K+-free medium will cause the re-
lease of Ca2+ from intracellular store and the entry of
Ca2+ into the cells through ROCC since VDCC are
inactivated in the absence of K+ [26,27]. Results in
Figures 3 and 4 show that preincubation with F1 signifi-
cantly decreased the Emax of the CaCl2-induced contrac-
tions in both media, suggesting that the vasodilatoryFigure 6 Effect of F1 on NA- and caffeine-induced contraction
in Ca2+-free solution. Aortic rings were preincubated with vehicle
(control) or BU (2 or 4 mg/ml) and NA (10-6 M) or caffeine
(45 mM) was added to trigger the contractions. Values are
mean ± S.E.M. (n = 6).effect of F1 is caused by blocking the influx of Ca2+ via
VDCC and ROCC.
Caffeine and NA were used to study the release of Ca2+
from intracellular sarcoreticular stores. Caffeine can
stimulate the ryanodine receptors [28] and NA can trigger
the activation of IP3 [29] receptor located at the SR in
order to cause the release of the Ca2+ from SR. In the
present study, it is found that the vasoconstriction induced
by both caffeine and NA were not affected by F1 (Figure 5).
Therefore, the vasodilatory effect of F1 does not seem to
be related to inhibition of ryanodine or IP3 receptors.
Potassium channels play a very crucial role in controlling
the vascular contractility. Efflux of K+ due to the opening
of the K+ channels in VSM will bring about membrane
hyperpolarisation, which in turn, will lead to the closure of
the VDCC and reduction of the Ca2+ entry, and finally
cause vasodilation [30]. In contrast, closure of the K+Table 3 The Rmax and pIC50 values of F1 in aortic rings
pretreated with various drugs
Drugs Rmax (%) pIC50
Control 98.39 ± 5.79 2.62 ± 0.09
TEA 97.61 ± 24.04 2.58 ± 0.30
Glibenclamide 73.23 ± 4.84* 2.19 ± 0.06*
4-aminopyridine 74.31 ± 6.89* 2.08 ± 0.05*
L-NAME 82.77 ± 13.12 2.49 ± 0.12
Indomethacin 68.15 ± 5.96* 2.37 ± 0.05*
ODQ 88.46 ± 6.49 2.51 ± 0.14
Methylene blue 107.98 ± 9.29 2.85 ± 0.17
Atropine 92.12 ± 2.64 2.53 ± 0.07
Propanolol 93.02 ± 8.93 2.46 ± 0.09
Values are means ± S.E.M (n = 6), *P < 0.05 compared with control (without
any drugs).
Figure 8 Concentration-relaxation curves for F1 in the isolated
rat aortic rings. The F1-induced relaxation was studied on
endothelium-intact, endothelium-denuded aortic rings and
endothelium-intact aortic rings preincubated with L-NAME or ODQ
or methylene blue or indomethacin. Values are mean ± S.E.M (n = 6).
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striction [31]. Four distinct types of K+ channels have been
identified in VSM, namely voltage-activated K+ channel,
Ca2+-activated K+ channels, ATP-sensitive K+ channels,
and inward rectifier K + channels) [32]. As demonstrated
by the results in Figure 6, F1 may be able to enhance or
stimulate the opening of both voltage-activated and
ATP-sensitive K+ channels, since preincubation with
glibenclamide and 4-aminopyridine significantly attenuated
its vasodilatory effect. On the other hand, Ca2+-activated
K+ channel may not be involved in the vasodilatory effect
of F1 since Rmax value of F1 was not significantly altered
with the preincubation of TEA.
Nitric oxide is the primary EDRF formed in the endo-
thelium that diffuses to the VSM to activate the solubleFigure 9 Concentration-relaxation curves for F1 in the isolated
rat aortic rings. The F1-induced relaxation was studied on
PE-precontracted endothelium-intact aortic rings preincubated with
atropine or propanolol. Value are mean ± S.E.M (n = 6).guanylyl cyclase. This enzyme will then catalyse the for-
mation of cyclic guanosine monophosphate (cGMP),
which in turn activates the protein kinase G (PKG). The
PKG will cause the phophorylation of myosin light-chain
kinase (MLCK) and subsequently decrease its activity,
leading to the dephosphorylation of myosin light chain
and thus causing vasorelaxation [33]. In addition, NO
also participates in the regulation of the level of smooth
muscle free Ca2+, which is the primary determinant of
contractions [34]. Prostacyclin is the lipid compound de-
rived enzymatically from fatty acid and it is the first
EDRF that was discovered earlier than NO [35]. It is
synthesised in both VSM and endothelial cells [36]. Re-
sults from the present studies show that removal of
endothelium did not cause significant changes in the
Rmax and pIC50 of F1-induced relaxation. This indicates
that endothelium may not be involved in the vasodila-
tory effect of F1. Similarly, there were also no significant
changes in the Rmax and pIC50 values for the aortic rings
preincubated with L-NAME, ODQ, and methylene blue
(Figure 7). These findings imply that F1 does not affect
the endothelium-derived NO production as well as the
NO-mediated pathway. To the contrary, significant re-
ductions in both Rmax and pIC50 were observed in the
aortic ring preincubated with indomethacin, the inhibi-
tor of the cyclo-oxygenase that participates in the pros-
tacyclin synthesis. Prostacyclin is synthesised in both
endothelium and VSM. The vasodilatory effect of F1 was
attenuated by the inhibition of cyclo-oxygenase but not
by the removal of endothelium, suggesting that F1 may
stimulate the release of prostacyclin from VSM.
The beta adrenoceptor acts by coupling with G pro-
tein. The activation of beta adrenoceptor stimulates
adenylyl cyclase which functions as a catalyst for the
conversion of adenosine triphosphate to cyclic adeno-
sine monophosphate. This in turn leads to the activation
of protein kinase A and vasodilation [37]. Muscarinic re-
ceptors are stimulated by the postganglionic cholinergic
neurons of either the parasympathetic or the sympathetic
cholinergic systems that mediate smooth muscle rela-
xation, glandular secretion, and modulation of cardiac rate
and force [38]. Results from the present study show that
there were no significant changes in the Rmax and pEC50
in the aortic rings preincubated with propanolol and atro-
pine (Figure 8). This suggests that beta adrenoceptor and
muscarinic receptor may not be involved in the vasodila-
tory effect of F1.
Phytochemcial screening of the compounds present in
F1 detected high amount of flavonoids. Flavonoids are
polyphenolic compounds that occur naturally in vegeta-
bles, fruits, seeds, nuts, barks and are an integral part of
the human diet [39]. Flavonoids belong to the low mo-
lecular weight group of polyphenol substances. The bio-
chemical activities of flavonoids and their metabolites
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tion of various moieties on the molecule. They can be
grouped into 8 major classes by their chemical struc-
tures that include flavones, flavanones, flavonols, cate-
chins, anthocyanidins, isoflavones, dihydroflavonols, and
chalcones [40]. Depending on their chemical structures,
these flavonoids have been found to possess a wide
range of pharmacological activities, such as antihyper-
tensive [41,42] and vasodilatory [43,44] activities.
In the present study, although the phytochemical
screening technique did not reveal the actual chemical
structures of the active compounds in F1, it helped to
show that the majority of compounds present in F1 are
flavonoids. Based on the evidence that F1 exhibits vaso-
dilatory activity and as well as containing flavonoids, it is
logical to postulate that the vasodilatory effect of F1
could possibly be attributed to the presence of flavonoid.
However more experiments need to be carried out in
order to confirm this association and to identify the
structure of the active compounds.
Conclusions
This study demonstrates conclusively that leaves of
G. procumbens contain potent vasodilatory substances,
more of them being found in the F1 subfraction of the BU
fraction. These results also further confirm previous find-
ings that the vasodilatory effects of BU were brought
about by blocking the calcium channels. In addition to the
Ca2+ channel-blocking activities, the active compounds
were also found to be able to open K+ channel as well as
to stimulate the production of prostacyclin. Phytochemical
analyses reveal that the putative compounds are probably
flavonoids in nature.
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